Note 9 - Segment Information and Disaggregated Revenue

9 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended March 31, 2022 and 2021 were $2,562 and $2,333, respectively and for the nine months ended March 31, 2022 and 2021 were $7,139 and $5,550, respectively.

Financial information relating to the three months ended March 31, 2022 and 2021 operations by business segment and disaggregated revenues was as follows:

		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2022	$	12,686	$	2,554	$	15,240	$	1,840	$	82	$	143
	2021		14,311		2,308		16,619		2,550		82		33
Other Nutraceutical Businesses	2022		386		8		394		142		1		-
	2021		428		25		453		111		1		-
Total Company	2022		13,072		2,562		15,634		1,982		83		143
	2021		14,739		2,333		17,072		2,661		83		33

Financial information relating to the nine months ended March 31, 2022 and 2021 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2022	$	34,559	$	7,077	$	41,636	$	4,691	$	244	$	451
	2021		39,803		5,474		45,277		6,875		250		147
Other Nutraceutical Businesses	2022		1,281		62		1,343		465		3		-
	2021		1,148		76		1,224		333		3		3
Total Company	2022		35,840		7,139		42,979		5,156		247		451
	2021		40,951		5,550		46,501		7,208		253		150

	Total Assets as of
	March 31,		June 30,
	2022		2021
Contract Manufacturing	$	23,027	$	21,333
Other Nutraceutical Businesses		4,670		4,107
Total Company	$	27,697	$	25,440